From reading the Annual Report, I would expect more action towards the end of the year. Market in general is due for another correction before then; already signs of a sell off yesterday (Wednesday).
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%